At present, it is unknown whether SGLT2 inhibitors are superior to other nephroprotective agents, such as finerenone (now under clinical investigation for non-diabetic CKD) [58] and sparsentan for IgAN [59]. This evidence concerns the gene SLC5A2 and chronic kidney disease.